|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for PLA2G2A |
 Gene summary |
| Basic gene Info. | Gene symbol | PLA2G2A |
| Gene name | phospholipase A2, group IIA (platelets, synovial fluid) | |
| Synonyms | MOM1|PLA2|PLA2B|PLA2L|PLA2S|PLAS1|sPLA2 | |
| Cytomap | UCSC genome browser: 1p35 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000300.3, NM_001161727.1,NM_001161728.1,NM_001161729.1, | |
| Description | GIIC sPLA2NPS-PLA2group IIA phospholipase A2non-pancreatic secretory phospholipase A2phosphatidylcholine 2-acylhydrolase 2Aphospholipase A2, membrane associated | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 172411 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000188257 | ||
| HPRD : 01397 | ||
| Vega : OTTHUMG00000002699 | ||
| Protein | UniProt: P14555 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_PLA2G2A | |
| BioGPS: 5320 | ||
| Pathway | NCI Pathway Interaction Database: PLA2G2A | |
| KEGG: PLA2G2A | ||
| REACTOME: PLA2G2A | ||
| Pathway Commons: PLA2G2A | ||
| Context | iHOP: PLA2G2A | |
| ligand binding site mutation search in PubMed: PLA2G2A | ||
| UCL Cancer Institute: PLA2G2A | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006644 | phospholipid metabolic process | 17069818 | GO:0046473 | phosphatidic acid metabolic process | 9032461 |
| Top |
| Ligand binding site mutations for PLA2G2A |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | C64 | C64R | LUAD | 1 | C64 | C63S | LUAD | 1 | I29 | K30N | PRAD | 1 | C64 | R62C | SKCM | 1 | Y41 | S40R | STAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for PLA2G2A |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | C64 | C63S | -1.6420774 | I29 | K30N | -1.2317216 | C64 | R62C | -1.2293213 | C64 | C64R | -0.77304145 | Y41 | S40R | -0.36039501 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for PLA2G2A from PDB |
| Top |
| Differential gene expression and gene-gene network for PLA2G2A |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for PLA2G2A |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0004153 | Atherosclerosis | 14 | AlteredExpression, Biomarker |
| umls:C1527249 | Colorectal Cancer | 6 | Biomarker, GeneticVariation |
| umls:C0009404 | Colorectal Neoplasms | 2 | Biomarker |
| umls:C0151744 | Myocardial Ischemia | 1 | Biomarker |
| umls:C0035126 | Reperfusion Injury | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for PLA2G2A |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved|investigational | DB00328 | Indomethacin | Small molecule |  |
| Approved|vet_approved | DB00586 | Diclofenac | Small molecule |  |
| Approved|nutraceutical | DB01381 | Ginkgo biloba | Small molecule |  |
| Experimental | DB01955 | 1,4-Butanediol | Small molecule |  |
| Experimental | DB02080 | 1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene | Small molecule |  |
| Approved | DB02325 | Isopropyl Alcohol | Small molecule |  |
| Experimental | DB02448 | N-Tridecanoic Acid | Small molecule |  |
| Experimental | DB02504 | [3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid | Small molecule |  |
| Experimental | DB02936 | 4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid | Small molecule |  |
| Experimental | DB03121 | 1-Benzyl-5-Methoxy-2-Methyl-1h-Indol-3-Yl)-Acetic Acid | Small molecule |  |
| Experimental | DB03471 | 6-Phenyl-4(R)-(7-Phenyl-Heptanoylamino)-Hexanoic Acid | Small molecule |  |
| Experimental | DB03784 | Elaidoylamide | Small molecule |  |
| Experimental | DB04112 | 1-Octadecyl-2-Acetamido-2-Deoxy-Sn-Glycerol-3-Phosphoethylmethyl Sulfide | Small molecule |  |
| Experimental | DB04287 | (S)-5-(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoylamino)-Pentanoic Acid | Small molecule |  |
| Approved | DB04786 | Suramin | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of PLA2G2A go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of PLA2G2A |
| Multiple alignments for P14555 in multiple species |
| LBS | AA sequence | # species | Species | A37 | TTGKEAALSYG | 1 | Homo sapiens | A37 | TTGKEPATRYS | 1 | Bos taurus | A37 | KTGKRADVSYG | 1 | Rattus norvegicus | A38 | TGKEAALSYGF | 1 | Homo sapiens | A38 | TGKEPATRYSF | 1 | Bos taurus | A38 | TGKRADVSYGF | 1 | Rattus norvegicus | C48 | FYGCHCGVGGR | 2 | Homo sapiens, Rattus norvegicus | C48 | FYGCYCGMSGR | 1 | Bos taurus | C64 | ATDRCCVTHDC | 1 | Homo sapiens | C64 | ATDWCCRAHDC | 1 | Bos taurus | C64 | ATDWCCVTHDC | 1 | Rattus norvegicus | D68 | CCVTHDCCYKR | 1 | Homo sapiens | D68 | CCRAHDCCYKN | 1 | Bos taurus | D68 | CCVTHDCCYNR | 1 | Rattus norvegicus | E75 | CYKRLEKRGCG | 1 | Homo sapiens | E75 | CYKNLESRGCR | 1 | Bos taurus | E75 | CYNRLEKRGCG | 1 | Rattus norvegicus | F118 | AAATCFARNKT | 1 | Homo sapiens | F118 | IAANCFAANLK | 1 | Bos taurus | F118 | AAAECFARNKK | 1 | Rattus norvegicus | F25 | GNLVNFHRMIK | 1 | Homo sapiens | F25 | GDLLNFRKMIK | 1 | Bos taurus | F25 | GSLLEFGQMIL | 1 | Rattus norvegicus | F43 | ALSYGFYGCHC | 1 | Homo sapiens | F43 | ATRYSFYGCYC | 1 | Bos taurus | F43 | DVSYGFYGCHC | 1 | Rattus norvegicus | G42 | AALSYGFYGCH | 1 | Homo sapiens | G42 | PATRYSFYGCY | 1 | Bos taurus | G42 | ADVSYGFYGCH | 1 | Rattus norvegicus | G45 | SYGFYGCHCGV | 2 | Homo sapiens, Rattus norvegicus | G45 | RYSFYGCYCGM | 1 | Bos taurus | G49 | YGCHCGVGGRG | 2 | Homo sapiens, Rattus norvegicus | G49 | YGCYCGMSGRG | 1 | Bos taurus | G51 | CHCGVGGRGSP | 2 | Homo sapiens, Rattus norvegicus | G51 | CYCGMSGRGTP | 1 | Bos taurus | H26 | NLVNFHRMIKL | 1 | Homo sapiens | H26 | DLLNFRKMIKL | 1 | Bos taurus | H26 | SLLEFGQMILF | 1 | Rattus norvegicus | H47 | GFYGCHCGVGG | 2 | Homo sapiens, Rattus norvegicus | H47 | SFYGCYCGMSG | 1 | Bos taurus | H67 | RCCVTHDCCYK | 1 | Homo sapiens | H67 | WCCRAHDCCYK | 1 | Bos taurus | H67 | WCCVTHDCCYN | 1 | Rattus norvegicus | I29 | NFHRMIKLTTG | 1 | Homo sapiens | I29 | NFRKMIKLTTG | 1 | Bos taurus | I29 | EFGQMILFKTG | 1 | Rattus norvegicus | K72 | HDCCYKRLEKR | 1 | Homo sapiens | K72 | HDCCYKNLESR | 1 | Bos taurus | K72 | HDCCYNRLEKR | 1 | Rattus norvegicus | K82 | RGCGTKFLSYK | 1 | Homo sapiens | K82 | RGCRTKFLKYN | 1 | Bos taurus | K82 | RGCGTKFLTYK | 1 | Rattus norvegicus | L22 | QAHGNLVNFHR | 1 | Homo sapiens | L22 | QVHGDLLNFRK | 1 | Bos taurus | L22 | QVQGSLLEFGQ | 1 | Rattus norvegicus | N134 | YQYYSNKHCRG | 1 | Homo sapiens | N134 | LRFYNKFRCRG | 1 | Bos taurus | N134 | YQFYPNKFCKG | 1 | Rattus norvegicus | V50 | GCHCGVGGRGS | 2 | Homo sapiens, Rattus norvegicus | V50 | GCYCGMSGRGT | 1 | Bos taurus | Y132 | KKYQYYSNKHC | 1 | Homo sapiens | Y132 | KKLRFYNKFRC | 1 | Bos taurus | Y132 | LKYQFYPNKFC | 1 | Rattus norvegicus | Y41 | EAALSYGFYGC | 1 | Homo sapiens | Y41 | EPATRYSFYGC | 1 | Bos taurus | Y41 | RADVSYGFYGC | 1 | Rattus norvegicus | Y44 | LSYGFYGCHCG | 1 | Homo sapiens | Y44 | TRYSFYGCYCG | 1 | Bos taurus | Y44 | VSYGFYGCHCG | 1 | Rattus norvegicus | Y71 | THDCCYKRLEK | 1 | Homo sapiens | Y71 | AHDCCYKNLES | 1 | Bos taurus | Y71 | THDCCYNRLEK | 1 | Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |